Novo Nordisk’s Wegovy is about to enter the Irish market but people will have to pay for it from their own pocket - for now ...

While the number of prescription fills for GLP-1 receptor agonists has continued to increase, health Insurance coverage for ...

In 2023, the United States marked a major milestone in the battle against a longstanding public health crisis: adult obesity rates dropped for the first time in a decade. Researchers pointed to GLP-1s ...

As China embarks on its three-year "weight management" campaign, Novo Nordisk has stepped forward with its powerful tools to ...

Despite a crowded GLP-1 drug development field, Structure's oral small molecule approach and strong financial position offer ...

Hims & Hers (HIMS), the millennial-skewed telehealth company, saw its stock tumble nearly 9% on Tuesday, as the company ...

Both semaglutide and tirzepatide would need big price cuts to be seen as a good buy for the US healthcare system.

(NYSE: FDX) had stocks drifting lower and set for another week of losses. Investors are trying to price in uncertainty regarding the Trump administration’s tariffs, which are set to go into effect on ...

Those drugs are commonly known by names such as Ozempic, Wegovy and Zepbound ... It found the number of people with no commercial insurance coverage for Zepbound has increased by more than ...

Novo Nordisk is a great pick to buy with the stock near its 52-week low. Vertex Pharmaceuticals is helping patients and ...

Discover why Gyre Therapeutics is rated 'Hold' amid volatile stock behavior, uncertain long-term prospects, and pending Phase ...